Professor of Medical Oncology, University Pittsburgh
Oncology
Dr. Adam M. Brufsky, MD
|
|
Give Review
Adam Brufsky practices Oncology. He went to University of Connecticut School of Medicine. University of Connecticut School of Medicine is ranked 60/49 in Research/PrimaryCare. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Pittsburgh Magazine", "Top MD" and "Most Compassionate Doctor". Dr. Adam M. Brufsky has written publications. He has 61 publications published with PubMed. The lastest publication is: 'Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast Cancer.
- Neoadjuvant plus adjuvant bevacizumab in early breast Cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
- Prognostic factors and survival of patients with brain metastasis from breast Cancer who underwent craniotomy.
- Prevention of bone loss with risedronate in breast Cancer survivors: a randomized, controlled clinical trial.
- Utilizing microtubule dynamics inhibitor therapeutics in the management of patients with metastatic breast Cancer.
- Breast Cancer: Zoledronic acid-more than just a bone drug.
- Bisphosphonates in breast Cancer.
- Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast Cancer.
- Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway.
- Long-term survivor characteristics in HER2-positive metastatic breast Cancer from registHER.
- Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast Cancer.
- Metastasis of Breast Carcinoma to the Maxillary Sinus.
- The bone substudy of MA.27: does bone make a difference?
- Treatment of HER2-positive breast Cancer: looking backwards briefly.
- Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast Cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
- Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast Cancer.
- Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study.
- Breast Cancer index identifies early-stage estrogen receptor-positive breast Cancer patients at risk for early- and late-distant recurrence.
- How to develop and deLiver pathway-based care.
- Persistent Postmastectomy Pain in Breast Cancer Survivors: Analysis of Clinical, Demographic, and Psychosocial Factors.
- Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.
- Breast Cancer survivorship symptom management: current perspective and future development.
- Persistent pain in postmastectomy patients: comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain.
- Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP ...
- Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid.
- Adjuvant treatment of HER2-positive breast Cancer: winning efforts continue to improve HER2-positive patient outcome long-term.
- Lymphedema prevention and early intervention: a worthy goal.
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second...
- Final 5-year results of Z-FAST trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole.
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER.
- RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth ...
- Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial.
- Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast Cancer. Clinical article.
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast Cancer.
- Erratum: Immunohistochemical Surrogate Markers of Breast Cancer Molecular Classes Predicts Response to Neoadjuvant Chemotherapy.
- Localization of CD44 and CD90 positive cells to the invasive front of Breast tumors.
- Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic bre...
- The evolving role of bone-conserving therapy in patients with breast Cancer.
- The role of bisphosphonates in the adjuvant setting for breast Cancer.
- Immunohistochemical surrogate markers of breast Cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
- Randomized controlled trial of the Breast Cancer Recovery Program for women with breast Cancer-related lymphedema.
- Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast Cancer receiving adjuvant letrozole: Z-FAST stu...
- Histopathologic variables predict Oncotype DX recurrence score.
- RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast Cancer.
- What do perceived cognitive problems reflect?
- Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
- Bone health issues in women with early-stage breast Cancer receiving aromatase inhibitors.
- Managing bone loss in women with early-stage breast Cancer receiving aromatase inhibitors.
- Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast Cancer.
- Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal ...
- Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast Cancer.
- Long-term survivors after gamma knife radiosurgery for brain metastases.
- Single-fraction radiosurgery for the treatment of spinal Breast metastases.
- Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients ...
- The nurse as principal investigator in a pharmaceutically sponsored drug trial: considerations and challenges.
- The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events.
- Evaluation of the OncoTCap (Oncology Thinking Cap) simulation in teaching medical students about clinical trials: some successes and some surprises.
- High prevalence of screening-detected prostate Cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey.
- First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER.
Schools
Univ Of Ct Sch Of Med
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Anemia
- Bladder Cancer
- Breast Cancer
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Pittsburgh Magazine
- Top MD
- Most Compassionate Doctor
Education
-
Brigham and Women's Hospital -
University of Connecticut School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1518939537 | |
| NPPES Provider LastName | BRUFSKY | |
| NPPES Provider FirstName | ADAM | |
| NPPES Provider ZIPCode | 152133108 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1297.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 74.0 | |
| Percent Opioid Claims | 5.71 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518939537 |
| Last Name Of The Provider | BRUFSKY |
| First Name Of The Provider | ADAM |
| View All |
Similar Doctors
|
|
Dr. Narinder K. Malhotra, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane M. Raymond, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roy E. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Min E. Sun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maricel D. Castaner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel C. Jankowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven A. Burton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Vanderweele, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Bress, MD |
|
|
Dr. Jason Bierenbaum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna M. Johnsen, MD |